Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study

被引：0
|
作者：
Barth, D. [1 ]
Moik, F. [1 ]
Steinlechner, S. M. [1 ]
Posch, F. [2 ]
Schlintl, V. [1 ]
Koch, L. [3 ]
John, N. [4 ]
Wurm, R. [4 ]
Pichler, M. [1 ]
Bauernhofer, T. [1 ]
Reimann, P. [5 ]
Wohlkoenig, C. [4 ]
Richtig, E. [3 ]
Winder, T. [5 ]
Preusser, M. [6 ]
Jost, P. J. [1 ]
Ay, C. [7 ]
Gerger, A. [1 ]
Terbuch, A. [1 ]
Riedl, J. M. [1 ]
机构：
[1] Med Univ Graz, Div Oncol, Dept Internal Med, Graz, Austria
[2] Med Univ Graz, Div Hematol, Dept Internal Med, Graz, Austria
[3] Med Univ Graz, Dept Dermatol, Graz, Austria
[4] Med Univ Graz, Div Pulmonol, Dept Internal Med, Graz, Austria
[5] Landeskrankenhaus Feldkirch, Dept Oncol, Feldkirch, Austria
[6] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[7] Med Univ Vienna, Dept Med 1, Clin Div Haematol & Haemostaseol, MedUni Wien, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2917
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
194P
引用
收藏
页码：S259 / S259
页数：1
相关论文
共 50 条
  • [21] C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study
    Povoa, Pedro
    Teixeira-Pinto, Armando M.
    Carneiro, Antonio H.
    CRITICAL CARE, 2011, 15 (04):
  • [22] Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
    Yosuke Yasuda
    Kazutaka Saito
    Takeshi Yuasa
    Sho Uehara
    Naoko Kawamura
    Minato Yokoyama
    Junichiro Ishioka
    Yoh Matsuoka
    Shinya Yamamoto
    Tetsuo Okuno
    Junji Yonese
    Kazunori Kihara
    Yasuhisa Fujii
    International Journal of Clinical Oncology, 2017, 22 : 1081 - 1086
  • [23] Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
    Yasuda, Yosuke
    Saito, Kazutaka
    Yuasa, Takeshi
    Uehara, Sho
    Kawamura, Naoko
    Yokoyama, Minato
    Ishioka, Junichiro
    Matsuoka, Yoh
    Yamamoto, Shinya
    Okuno, Tetsuo
    Yonese, Junji
    Kihara, Kazunori
    Fujii, Yasuhisa
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (06) : 1081 - 1086
  • [24] Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer
    Masatoshi Maki
    Ryo Takada
    Akihiko Taniguchi
    Naoyuki Nomura
    Seiichiro Kuramoto
    Yuki Chiko
    Toshiaki Okada
    Seiji Saito
    Koji Tamura
    Journal of Pharmaceutical Health Care and Sciences, 8
  • [25] Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer
    Maki, Masatoshi
    Takada, Ryo
    Taniguchi, Akihiko
    Nomura, Naoyuki
    Kuramoto, Seiichiro
    Chiko, Yuki
    Okada, Toshiaki
    Saito, Seiji
    Tamura, Koji
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2022, 8 (01)
  • [26] The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
    Han, Cheng-Long
    Meng, Guang-Xiao
    Ding, Zi-Niu
    Dong, Zhao-Ru
    Chen, Zhi-Qiang
    Hong, Jian-Guo
    Yan, Lun-Jie
    Liu, Hui
    Tian, Bao-Wen
    Yang, Long-Shan
    Xue, Jun-Shuai
    Li, Tao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study
    Posch, F.
    Barth, D.
    Brueckl, W. M.
    Zeitler, G.
    Foris, V.
    Mollnar, S.
    Stotz, M.
    Rossmann, C. H.
    Terbuch, A.
    Balic, M.
    Niedrist, T.
    Bertsch, T.
    Stoeger, H.
    Pichler, M.
    Olschewski, H.
    Absenger, G.
    Ficker, J. H.
    Gerger, A.
    Riedl, J. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S286 - S286
  • [28] C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study
    Morikawa, Toshiharu
    Naiki, Taku
    Sugiyama, Yosuke
    Naiki-Ito, Aya
    Nagai, Takashi
    Etani, Toshiki
    Iida, Keitaro
    Isobe, Teruki
    Noda, Yusuke
    Shimizu, Nobuhiko
    Aoki, Maria
    Gonda, Masakazu
    Banno, Rika
    Kubota, Hiroki
    Ando, Ryosuke
    Umemoto, Yukihiro
    Kawai, Noriyasu
    Yasui, Takahiro
    CANCERS, 2024, 16 (09)
  • [29] Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
    Wang, Haoyu
    Yang, Ruiyuan
    Zhou, Ke
    Wang, Suyan
    Cheng, Cheng
    Liu, Dan
    Li, Weimin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 124
  • [30] C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study
    Riedl, Jakob M.
    Barth, Dominik A.
    Brueckl, Wolfgang M.
    Zeitler, Gloria
    Foris, Vasile
    Mollnar, Stefanie
    Stotz, Michael
    Rossmann, Christopher H.
    Terbuch, Angelika
    Balic, Marija
    Niedrist, Tobias
    Bertsch, Thomas
    Stoeger, Herbert
    Pichler, Martin
    Olschewski, Horst
    Absenger, Gudrun
    Ficker, Joachim H.
    Gerger, Armin
    Posch, Florian
    CANCERS, 2020, 12 (08) : 1 - 21
12345